CN103209683B - 角鲨胺的眼用制剂 - Google Patents

角鲨胺的眼用制剂 Download PDF

Info

Publication number
CN103209683B
CN103209683B CN201180047840.8A CN201180047840A CN103209683B CN 103209683 B CN103209683 B CN 103209683B CN 201180047840 A CN201180047840 A CN 201180047840A CN 103209683 B CN103209683 B CN 103209683B
Authority
CN
China
Prior art keywords
composition
squalamine
eye
formulation
macular degeneration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180047840.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN103209683A (zh
Inventor
I·B·塔拉波雷瓦拉
S·I·巴肯罗斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neubase Therapeutics Inc
Original Assignee
OHR Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OHR Pharmaceutical Inc filed Critical OHR Pharmaceutical Inc
Priority to CN201610553185.8A priority Critical patent/CN106074362A/zh
Publication of CN103209683A publication Critical patent/CN103209683A/zh
Application granted granted Critical
Publication of CN103209683B publication Critical patent/CN103209683B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201180047840.8A 2010-08-17 2011-08-16 角鲨胺的眼用制剂 Expired - Fee Related CN103209683B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610553185.8A CN106074362A (zh) 2010-08-17 2011-08-16 角鲨胺的眼用制剂

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37452410P 2010-08-17 2010-08-17
US61/374,524 2010-08-17
PCT/US2011/047920 WO2012024298A1 (en) 2010-08-17 2011-08-16 Ophthalmic formulations of squalamine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201610553185.8A Division CN106074362A (zh) 2010-08-17 2011-08-16 角鲨胺的眼用制剂

Publications (2)

Publication Number Publication Date
CN103209683A CN103209683A (zh) 2013-07-17
CN103209683B true CN103209683B (zh) 2016-08-31

Family

ID=44533189

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201180047840.8A Expired - Fee Related CN103209683B (zh) 2010-08-17 2011-08-16 角鲨胺的眼用制剂
CN201610553185.8A Pending CN106074362A (zh) 2010-08-17 2011-08-16 角鲨胺的眼用制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201610553185.8A Pending CN106074362A (zh) 2010-08-17 2011-08-16 角鲨胺的眼用制剂

Country Status (9)

Country Link
US (2) US20130281420A1 (cg-RX-API-DMAC10.html)
EP (1) EP2605752A1 (cg-RX-API-DMAC10.html)
JP (2) JP5956992B2 (cg-RX-API-DMAC10.html)
KR (1) KR101845107B1 (cg-RX-API-DMAC10.html)
CN (2) CN103209683B (cg-RX-API-DMAC10.html)
AU (1) AU2011292160B2 (cg-RX-API-DMAC10.html)
CA (1) CA2808628A1 (cg-RX-API-DMAC10.html)
MX (1) MX2013001870A (cg-RX-API-DMAC10.html)
WO (1) WO2012024298A1 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9681951B2 (en) 2013-03-14 2017-06-20 Edwards Lifesciences Cardiaq Llc Prosthesis with outer skirt and anchors
AU2015317531B2 (en) * 2014-09-17 2020-11-19 Panoptica, Inc. Ocular formulations for drug-delivery and protection of the anterior segment of the eye
AR106691A1 (es) * 2015-11-13 2018-02-07 Ohr Pharmaceutical Inc Formulaciones oftálmicas de escualamina
WO2017083800A1 (en) * 2015-11-13 2017-05-18 Ohr Pharmaceutical, Inc. Occult cnv size as a predictor for treatment with squalamine
KR20180036580A (ko) 2016-09-30 2018-04-09 주식회사 유스바이오팜 수가용화(水加溶化)된 우르소데옥시콜산을 함유하는 염증성 피부질환 또는 중증 소양증 예방 또는 치료용 조성물
US11241443B2 (en) * 2017-04-07 2022-02-08 Sun Pharma Advanced Research Company Ltd. Ophthalmic solution of bimatoprost
IT202300017430A1 (it) * 2023-08-22 2025-02-22 Service Biotech srl Soluzione oftalmica in forma di collirio contenente una isoforma umana ricombinante di manganese superossido dismutasi (rmnsod) per la cura di patologie dell’occhio

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006119211A2 (en) * 2005-05-02 2006-11-09 Genaera Corporation Methods and compositions for treating ocular disorders
CN101262886A (zh) * 2005-07-15 2008-09-10 视可舒研究公司 用于给药眼科活性剂的制剂和方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0444778A1 (en) * 1990-02-14 1991-09-04 Alcon Laboratories, Inc. Use of alkyl saccharides to enhance the penetration of drugs
US5631004A (en) * 1993-09-30 1997-05-20 Alcon Laboratories, Inc. Use of sustained release antibiotic compositions in ophthalmic surgical procedures
AU4772696A (en) * 1996-01-26 1997-08-20 Alcon Laboratories, Inc. Use of squalamine and its analogues in ophthalmic compositions
US6262283B1 (en) 1996-12-06 2001-07-17 Magainin Pharmaceuticals Inc. Stereoselective synthesis of 24-hydroxylated compounds useful for the preparation of aminosterols, vitamin D analogs, and other compounds
US20050234018A1 (en) * 2004-04-15 2005-10-20 Allergan, Inc. Drug delivery to the back of the eye
US20080233053A1 (en) * 2005-02-07 2008-09-25 Pharmalight Inc. Method and Device for Ophthalmic Administration of Active Pharmaceutical Ingredients
US7981876B2 (en) * 2005-04-25 2011-07-19 Ohr Pharmaceuticals, Inc. Polymorphic and amorphous salt forms of squalamine dilactate
EP1904108B1 (en) * 2005-07-15 2011-11-30 Chakshu Research, Inc. Ophthalmological formulation comprising methylsulfonylmethane and ciprofloxacin
US7893040B2 (en) * 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
WO2007061739A2 (en) * 2005-11-21 2007-05-31 Schering-Plough Ltd. Pharmaceutical compositions comprising buprenorphine
US8216575B2 (en) 2006-03-31 2012-07-10 Chengdu Kanghong Biotechnologies Co., Ltd. Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
WO2008031113A2 (en) * 2006-09-08 2008-03-13 Genaera Corporation Improved method for inhibition of neovascularization
GB0625844D0 (en) * 2006-12-22 2007-02-07 Daniolabs Ltd The treatment of macular degeneration
US8821870B2 (en) 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006119211A2 (en) * 2005-05-02 2006-11-09 Genaera Corporation Methods and compositions for treating ocular disorders
CN101262886A (zh) * 2005-07-15 2008-09-10 视可舒研究公司 用于给药眼科活性剂的制剂和方法

Also Published As

Publication number Publication date
JP6214726B2 (ja) 2017-10-18
WO2012024298A1 (en) 2012-02-23
CN106074362A (zh) 2016-11-09
JP5956992B2 (ja) 2016-07-27
KR20140021505A (ko) 2014-02-20
CN103209683A (zh) 2013-07-17
AU2011292160B2 (en) 2015-09-03
MX2013001870A (es) 2013-07-03
JP2016166250A (ja) 2016-09-15
US20150342874A1 (en) 2015-12-03
KR101845107B1 (ko) 2018-04-03
AU2011292160A1 (en) 2013-03-14
US20130281420A1 (en) 2013-10-24
JP2013537551A (ja) 2013-10-03
EP2605752A1 (en) 2013-06-26
CA2808628A1 (en) 2012-02-23

Similar Documents

Publication Publication Date Title
JP6214726B2 (ja) スクアラミンの眼用製剤
JP3683595B2 (ja) セチリジン含有抗アレルギー点眼点鼻用組成物
US20040132704A1 (en) Use of oculosurface selective glucocorticoid in the treatment of dry eye
US20190328772A1 (en) Ophthalmic compositions comprising a cyclodextrin as sole active agent
JP2025513090A (ja) 眼疾患の治療のためのミコフェノール酸及び／又はベタメタゾンの医薬組成物
CN103079595B (zh) 滴眼用水性组合物
CN110237031B (zh) 包含释放一氧化氮的前列酰胺的眼用组合物
JP2026035663A (ja) 高分子量ヒアルロン酸の眼科用薬物輸送ビヒクルとしての使用
WO2017083799A1 (en) Ophthalmic formulations of squalamine
JP2009528390A (ja) 薬用ラトランキュリン製剤
AU2015258244C1 (en) Ophthalmic formulations of squalamine
HK1185566A (zh) 角鲨胺的眼用制剂
HK1185566B (zh) 角鲨胺的眼用制剂
HK1228731A1 (en) Ophthalmic formulations of squalamine
CA2956037A1 (en) Stable preservative free ophthalmic formulations of opioid antagonists
HK40030606B (en) Ophthalmic compositions containing a nitric oxide releasing prostamide
HK40030606A (en) Ophthalmic compositions containing a nitric oxide releasing prostamide
HK40013822A (en) Ophthalmic compositions containing a nitric oxide releasing prostamide
HK40013822B (en) Ophthalmic compositions containing a nitric oxide releasing prostamide

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1185566

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1185566

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160831

Termination date: 20180816

CF01 Termination of patent right due to non-payment of annual fee